CAMP4 teams up with BioMarin to advance RNA-targeting meds

Cambridge, USA-based CAMP4 Therapeutics has announced a new research collaboration with BioMarin Pharmaceutical (Nasdaq: BMRN) aimed at advancing novel therapeutics that increase protein levels by targeting regulatory RNA (regRNA) sequences, which are key elements controlling gene expression.

CAMP4 is developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases.

Financial terms of the accord have not ben disclosed, other that noting BioMarin has the right to select two targets identified by CAMP4’s RAP Platform to advance into clinical development.